An outbreak associated with a moringa supplement, which has now been declared resolved, involved a strain of Salmonella that is extensively resistant to drugs—specifically one that carries the NDM-1 carbapenemase gene, making it impervious to the majority of antibiotics, including carbapenems that are typically viewed as last-resort medications. The outbreak of Rosabella brand moringa powder impacted 10 individuals across 8 states from September 2025 to January 2026, attributed to Salmonella Kentucky and Salmonella Newport strains, with a hospitalization rate of 50 percent. The CDC released clinical guidance advising healthcare providers to customize antibiotic therapies based on susceptibility testing results and to seek infectious disease expertise for affected patients. The presence of NDM-1 bearing Salmonella strains in dietary supplements raises significant public health alarms.
